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Drug molecules not only interact with specific targets, but also alter the state and function of the associated biological
network. How to design drugs and evaluate their functions at the systems level becomes a key issue in highly efficient
and low–side-effect drug design. The arachidonic acid metabolic network is the network that produces inflammatory
mediators, in which several enzymes, including cyclooxygenase-2 (COX-2), have been used as targets for anti-
inflammatory drugs. However, neither the century-old nonsteriodal anti-inflammatory drugs nor the recently
revocatory Vioxx have provided completely successful anti-inflammatory treatment. To gain more insights into the
anti-inflammatory drug design, the authors have studied the dynamic properties of arachidonic acid (AA) metabolic
network in human polymorphous leukocytes. Metabolic flux, exogenous AA effects, and drug efficacy have been
analyzed using ordinary differential equations. The flux balance in the AA network was found to be important for
efficient and safe drug design. When only the 5-lipoxygenase (5-LOX) inhibitor was used, the flux of the COX-2
pathway was increased significantly, showing that a single functional inhibitor cannot effectively control the
production of inflammatory mediators. When both COX-2 and 5-LOX were blocked, the production of inflammatory
mediators could be completely shut off. The authors have also investigated the differences between a dual-functional
COX-2 and 5-LOX inhibitor and a mixture of these two types of inhibitors. Their work provides an example for the
integration of systems biology and drug discovery.
Citation: Yang K, Ma W, Liang H, Ouyang Q, Tang C, et al. (2007) Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol 3(3): e55. doi:10.1371/
journal.pcbi.0030055
Introduction
Nonsteriodal anti-inﬂammatory drugs (NSAIDs) (e.g., as-
pirin) are widely used for the treatment of musculoskeletal
pain and other conditions. In the US, more than 1% of the
population uses NSAIDs daily [1], and the market for NSAIDs
now amounts to more than $6 billion annually worldwide [2].
Although NSAIDs do alleviate the aches and pains, these
drugs have undesirable side effects on the gastrointestinal
tract and the central nervous system in addition to the
potential exacerbation of conditions such as asthma [1]. The
ﬁndings that cyclooxygenase-2 (COX-2) plays a major role in
inﬂammation, and that inhibition of COX-1 causes gastro-
intestinal toxicity and mild bleeding diathesis [3], had
suggested that selective COX-2 inhibitor would be an
effective anti-inﬂammatory drug with low gastrointestinal
side effects [4]. Ironically, the unexpected cardiovascular side
effects of selective COX-2 inhibitors have surfaced [5,6]. Thus,
on September 30, 2004, Merck & Company announced a
voluntary withdrawal of the company’s COX-2 inhibitor,
VIOXX (rofecoxib) [7]. Other FDA-approved COX-2 inhib-
itors, such as celecoxib (Celebrex) and valdecoxib (Bextra),
are being re-evaluated [8–10]. Despite years of studies, safe
anti-inﬂammatory drug design remains a great challenge.
Failures in anti-inﬂammatory drug design illustrate the
limitations of the current drug discovery paradigm. A steady
waning in the productivity of the pharmaceutical industry in
the past decade has been observed. This decline coincides
with the introduction of target-based drug discovery [11].
Recently, medicinal chemists have started to think about drug
discovery from a systems biology perspective [12,13]. Studying
the cross-talks between biological responses rather than one
by one may provide a better understanding of disease
development and achieve accurate evaluation on drug
efﬁcacy and toxicity [14,15]. This new approach has been
applied to safe drug design [16,17]. For example, the former
SmithKline Beecham (now GlaxoSmithKline, http://www.gsk.
com) focused on the blood coagulation cascade biochemical
network [18,19]. Armed with a good understanding of the
disease from the regulatory network level, the company used
model predictions to develop a fully humanized anti–Factor
IX antibody that has entered clinical trials. Rajasethupathy et
al. have recently reviewed advances in the practical applica-
tions of systems biology to drug discovery [20]. These
researchers promote the development of network-based drug
design, which devises drug-treatment strategies from the level
of the disease system using computational models and high-
throughput experiments.
In this paper, we study the dynamic properties of the
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morphonuclear leukocytes (PMNs) in the hope of gaining
more insights into anti-inﬂammatory drug design. An
ordinary differential equation (ODE) model of the AA
metabolic network was developed. Flux analysis and simu-
lation on the addition of exogenous AA were performed to
study the network balance. The therapeutic effects of anti-
inﬂammatory inhibitors were simulated, and the difference
between dual functional COX-2 and 5-lipoxygenase (5-LOX)
inhibitors and the mixture of these two types of inhibitors
was studied. Corresponding experiments on the introduction
of exogenous AA, COX-2, and 5-LOX inhibitors were
performed and were found to be consistent with model
predictions. Our work shows that ﬂux balance is important
for the efﬁcacy and safety of the drugs. Compared with
traditional single-target drugs, drugs against multiple targets
can control the network balance and lead to safer treatment.
Results
The Metabolic Network of AA in Human PMNs
Inﬂammation is a type of nonspeciﬁc immune response to
infection, irritation, or other injury. It is characterized by
redness, swelling, pain, and sometimes loss of function. When
harmful agents invade the human body, inﬂammatory
mediators are released by immune cells. This release causes
vasodilation, emigration of neutrophils, chemotaxis, and
increased vascular permeability. AA is the precursor of
inﬂammatory mediators, including prostaglandins (PGs) and
leukotrienes (LTs). Extensive researches on the metabolism of
AA in human PMNs have been performed. Thus, based on the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [21] and
a survey of the literature (Figure 1; see details in Protocol S1),
a computational model of the AA metabolic network in
human PMNs was constructed (Dataset S1).
The production of inﬂammatory mediators is initiated by
inﬂammatory stimuli that activate phospholipase A2. This
enzyme catalyzes the hydrolysis of the sn-2 position of the
membrane glycerophospholipids to release AA. Two separate
pathways produce inﬂammatory mediators. One is initiated
by COX-2 and produces PGs, while the other is initiated by 5-
LOX and produces LTs. PGE2, LTA4, and LTB4 are the major
inﬂammatory mediators in our model. Once PMNs have been
activated by inﬂammatory stimuli, the cells release inﬂam-
matory mediators and cause accumulation and activation of
other cells. A series of ODEs was established to simulate
unicellular behavior (see details in Materials and Methods),
which included 24 initial concentrations and 45 reaction
constants (see details in Protocol S1). A total of 23 reaction
constants was taken from experimental values, while the
others were obtained by ﬁtting the calculated production of
LTB4 and its x-oxidation products (x-LTB4) to experimental
data [22] (Figure 2 and Tables S1–S2). The parameter set that
ﬁt the experimental data well was chosen for further studies.
Dynamic Properties of the Network
Flux analysis was performed on the main network path-
ways, which included the 5-LOX, 15-LOX, and COX-2
pathways. The result of the 12-LOX pathway analysis was
not shown here due to its weak effect on other pathways in
the current network [23]. Figure 3A shows simulations of 30
min. In the ﬁrst 5 min, following the activation by
inﬂammatory stimuli, the ﬂux of the 5-LOX pathway was
the largest and was responsible for the major metabolism of
AA. As the result of negative feedback regulations (e.g., the
suicide inhibition of LTA4H by LTA4), the ﬂux of the 5-LOX
pathway decreased along with time, while the ﬂux of the 15-
LOX pathway increased. Ultimately, the 15-LOX pathway ﬂux
became the largest after the ﬁrst 5 min. During the 30-min
simulation, the ﬂux of the COX-2 pathway remained small
and played the least important role in the AA metabolic
network in human PMNs. The ﬁrst 10 min was critical for the
production of LTs, while PGs continued to accumulate with
time. These ﬁndings are consistent with previous experimen-
tal data [24,25] that showed that LTs rather than PGs are the
main inﬂammatory mediators produced in human PMNs.
Further simulations with different exogenous AA concen-
trations were performed. It seems logical to postulate that
more AA would produce more inﬂammatory mediators
because AA was the only source of LTs and PGs in our
model; however, the simulation results interestingly showed
that the output of LTs decreased with the concomitant
increase of exogenous AA (Figure 4A and 4D). This decrease
was the result of the negative-feedback mechanisms in the 5-
LOX pathway. The additional AA is mainly metabolized
through the 15-LOX pathway. Further experiments were
performed to validate this assumption (see details in
Materials and Methods). A decrease of LTs was observed
when more than 0.5 mM AA was added to PMNs. The output
of (15S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15-
HETE) increased at the same time (Figure 4C and 4B). Thus,
the simulation predictions are qualitatively consistent with
the experimental results.
Simulating the Therapeutic Effects of Anti-Inflammatory
Inhibitors
Simulations on widely used anti-inﬂammatory inhibitors,
including 5-LOX inhibitor, COX-2 inhibitor, and a combi-
nation of the two, were performed (Figure 3). The COX-2
inhibitor increased the ﬂux through the 15-LOX pathway,
while the ﬂux through the 5-LOX pathway remained almost
constant. The reason is that the effect of COX-2 pathway in
the current model is weak in the early stage of AA metabolism
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Author Summary
Inflammation is a basic way in which the body reacts to infection,
irritation, or other injury. When it is uncontrolled and misdirected, it
causes diseases such as rheumatoid arthritis, inflammatory bowel
disease, asthma, and others. In the United States, more than 1% of
the population uses nonsteroidal anti-inflammatory drugs, such as
aspirin, ibuprofen, or naproxen, daily to relieve aches and pains.
However, these drugs have undesirable side effects. The withdrawal
of VIOXX (rofecoxib; Merck, http://www.merck.com) in 2004 has
given a good lesson on safety problems. To assist the design of safe
anti-inflammatory drugs, we have constructed a computational
model of the arachidonic acid (AA) metabolic network in human
polymorphous leukocytes. By analyzing the flux changes upon drug
treatment in this metabolic network, drugs against multiple targets
were found to be capable of reducing toxicity as they exhibited
balanced control of the system. The model of the AA metabolic
network provides helpful information for anti-inflammatory drug
discovery. This work sets an example for the integration of systems
biology and drug discovery.
The Arachidonic Acid Metabolic Networkand becomes more evident with time. The 5-LOX inhibitor
induced the peak ﬂux immediately after initiating the
metabolism in both the COX-2 and the 15-LOX pathways.
When both the COX-2 and 5-LOX inhibitors were intro-
duced, the COX-2 and 5-LOX pathways were shut off, and the
majority of the ﬂux went through the 15-LOX pathway. These
simulation results showed that single-target anti-inﬂamma-
tory drugs cannot stop the production of all inﬂammatory
mediators, and that the combination of the 5-LOX and COX-
2 inhibitors would likely yield better therapeutic results. All
of the inhibitors increased the production of 15-HETE, which
was consistent with our experimental results (Figure 5).
We then did further simulation on the combination of 5-
LOX inhibitor and COX inhibitor. There are two strategies
for this combination: developing dual functional COX-2 and
5-LOX inhibitors, or using a mixture of these two types of
inhibitors. A few papers have been published on the
development of these two anti-inﬂammatory strategies, and
some drug candidates have already been in clinical tests [26–
31]. When using a combination of inhibitors, two issues need
to be considered: one is the mixing ratio (MR) of different
single-functional inhibitors, which makes great contributions
to the efﬁcacy and safety of the mixture; the other is the
relative inhibition constant to different enzymes (DR), which
decides the therapeutic effect of the dual-functional inhib-
itor. The efﬁcacy of the dual-functional COX-2 and 5-LOX
inhibitor and the mixture with different concentrations and
DR/MR values was investigated and compared. To ensure the
equality in the comparison, the same total inhibition ability
(KiCOX-2 3 Ki5-LOX; see details in Materials and Methods) and
the same total concentration of inhibitors were used in the
simulations. The inhibition intensity on the production of
LTs and PGs was calculated to evaluate the efﬁcacy of
inhibitors (see details in Materials and Methods).
As shown in Figure 6A, for the mixture, the inhibitors had
the largest effective concentration region when MR was close
Figure 1. The AA Metabolic Network in Human PMNs
AA is metabolized through three main pathways: the 5-LOX pathway (red line), the 15-LOX pathway (blue line), and the COX-2 pathway (green line).
PGE2, LTA4, and LTB4 are the major inflammatory mediators produced in the COX-2 and 5-LOX pathways. A total of 24 feedback loops, which are
involved in the network, make important contributions to the regulation of inflammatory mediators.
doi:10.1371/journal.pcbi.0030055.g001
Figure 2. Comparison of the Experimental Data and Computational Results
PMNs (20 310
6 cells/ml) were incubated at 37 8C with 10 lM A23187 (a calcium ionophore) (A) and 10 lM A23187 þ 30 lM AA (B), respectively. The
calculated results (line without star: red for LTB4 and blue for x-LTB4) fit well to experimental data [22] (line with star: red for LTB4 and blue for x-LTB4),
considering experimental error.
doi:10.1371/journal.pcbi.0030055.g002
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The Arachidonic Acid Metabolic Networkto the relative activity (ER) of the two enzymes (see deﬁnition
in Materials and Methods); that is, the enzymes can be
inhibited to more than 90% if the total inhibitor concen-
tration (CIt) was larger than approximately 1% of the total
concentration of 5-LOX and COX-2 (CEt). When CIt was less
than 1% of CEt, the enzymes cannot be effectively inhibited.
When MR deviated from ER, the effective concentration
region of the inhibitors became much smaller (e.g., when MR
deviated from ER by an order of 10
4), strong inhibition
(.90%) was achieved only when CIt was about ten times larger
than the CEt. Davies et al. [32] have reviewed the clinical
pharmacokinetics of a COX-2–selective inhibitor, meloxicam.
The maximum plasma concentration of this compound is
from 0.531 to 5.35 mg/l after application of clinical dosage (5–
30 mg) to volunteers, which is about 0.3 to 3 times the CEt in
our model. Thus, in general clinical treatments, the mixture of
compounds might be effective in a quite broad region of MR/
ER (about 0.001 to 1,000). If MR deviates too much from ER,
then the clinical dosage will not be effective.
For the dual-functional inhibitor, the compound also had
the largest effective concentration region when DR was close
to ER (Figure 6B). However, the low concentration limit was
extended to as low as 10
 4 (CIt/CEt); that is, the dual-
functional inhibitor was much more effective compared with
the mixture of inhibitors when the concentration was low
(Figure 6C). If the dual-functional inhibitors and the mixture
have similar pharmacokinetic properties, and the same drug
dose is applied to patients, the dual-functional inhibitors will
be effective for a longer time than the mixture, as they are
active at low concentration. When DR deviated from ER, the
effective concentration region of the inhibitor also became
smaller. There was a similar trend when DR was larger than
ER. When DR was smaller than ER, noticeable inhibition
could be observed at very low inhibitor concentration.
Discussion
Development of safe anti-inﬂammatory drugs has been an
especially tough problem for a long time. Failures in selective
COX-2 inhibitors have provided a good lesson on the drug
safety problem. Thus, network-based drug design, following
the development of systems biology, should be useful for
ﬁnding safe therapeutic strategies from the level of the
disease network. In the current study, we used the AA
metabolic network in human PMNs as an example for the
network-based drug design study. A mathematical model for
the AA metabolic network in human PMNs was built using
ODEs to describe enzymatic reactions and feedback loops.
Some of the parameters were taken from published exper-
imental studies, and other parameters and initial conditions
were determined by ﬁtting to experimental curves of LTB4
and derivative production. The model was validated by
experiments on the inﬂuence of introducing exogenous AA
or inhibitors and was found to explain experimental data
well. However, as the network is complex, its robustness and
reliability need to be further validated in future studies.
Nevertheless, our AA metabolic network model can enhance
the understanding of the production time course of
inﬂammatory mediators, including LTs and PGs, and can be
used to assist anti-inﬂammatory drug design.
Figure 3. Flux Analysis on the Three Main Pathways: The 5-LOX Pathway, the 15-LOX Pathway, and the COX-2 Pathway
Four states were studied: the disease state with no addition of inhibitors (A), the inhibited state with addition of COX-2 inhibitor (B), addition of 5-LOX
inhibitor (C), or addition of both COX-2 and 5-LOX inhibitors (D). Red line, 5-LOX pathway; blue line, 15-LOX pathway; and green line, COX-2 pathway.
doi:10.1371/journal.pcbi.0030055.g003
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The Arachidonic Acid Metabolic NetworkNetwork dynamic properties were found to be important
for anti-inﬂammatory drug design targeting the AA network.
Results of ﬂux analysis, simulations, and experiments on the
effect of exogenous AA showed the complexity of a
compound’s behavior in a system. Due to the effect of
feedback regulations and other pathways in the network, the
effect of a molecule in a system may not be same as its effect
on a single point reaction. Thus, designing drugs from the
network system level is necessary. Performing model studies
combined with experiments would be an effective way to ﬁnd
safe drugs.
Single-target anti-inﬂammatory inhibitors were found to
have limitations based on simulations and experiments in the
current work. Single-target inhibitors cannot achieve full
success in anti-inﬂammatory treatment because they cannot
control the production of both LTs and PGs at the same time.
Results in our studies suggest that the combination of the
COX-2 inhibitor and the 5-LOX inhibitor would have better
treatment. In fact, a dual COX-2/5-LOX inhibitor, licofelone
(ML3000) [33,34], has been successfully completed phase III
trials and is demonstrated to be superior in safety and equally
efﬁcacious for standard treatments of osteoarthritis.
Furthermore, multitarget anti-inﬂammatory drug efﬁcacy
was investigated. We simulated and compared the efﬁcacy of
dual COX-2/5-LOX inhibitors and the mixture of single-
functional COX-2 and 5-LOX inhibitors. The mixing ratio
and the relative inhibition constant were found to be
important to the efﬁcacy of the mixture and the dual-
Figure 4. Effects of Exogenous AA on the Network Balance
The 1-h output of x-LTB4 (20-OH-LTB4þ20-COOH-LTB4) (A) and 15-HETE (B) were calculated to evaluate changes in the 5-LOX pathway and the 15-LOX
pathway. To validate the simulation, experiments were performed: PMNs (1.66 310
7 cells/ml) were incubated at 37 8C with 10 lM A23187 (a calcium
ionophore) and arachidonic acid of different concentration for 1h. The output of x-LTB4 (C) and 15-HETE (D) were measured. The y-axis represents the
production with exogenous AA normalized against that without exogenous AA.
doi:10.1371/journal.pcbi.0030055.g004
Figure 5. The Production of 15-HETE in the Presence of Inhibitors
PMNs (1.66310
7 cells/ml) were preincubated with inhibitors for 10 min
at 37 8C and then were stimulated with 10 lM A23187 (a calcium
ionophore) for 1 h at 37 8C. MK886, an inhibitor of 5-LOX, was used to
block the production of LTs. CAY10404, an inhibitor of COX-2, was used
to block the production of PGs. The y-axis represents the production of
15-HETE with exogenous AA normalized against that without exogenous
AA.
doi:10.1371/journal.pcbi.0030055.g005
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The Arachidonic Acid Metabolic Networkfunctional inhibitor, respectively. Generally speaking, the
dual-functional inhibitor was effective in a larger concen-
tration range, making it more robust towards concentration
ﬂuctuations. Further studies are necessary to achieve a better
understanding of the difference between the dual-functional
inhibitor and the mixture of single-functional inhibitors.
Materials and Methods
Simulation methods. The mathematical model of the AA metabolic
network in PMNs. Based on KEGG and a survey of the literature, a
group of ODEs were devised to develop the mathematical model of
the AA metabolic network in human PMNs (see details in Protocol S1
and Dataset S1). Michaelis–Menten equations are used to describe the
catalysis in the network:
d½S 
dt
¼
Kcat½Et ½S 
Km þ½ S 
ð1Þ
where [S] is the concentration of substrate, [Et] is the total
concentration of enzyme, Kcat is turnover number, and Km is the
Michaelis–Menten constant.
If competitive reversible inhibitors are involved in the catalysis, the
equation is:
d½S 
dt
¼
Kcat½Et ½S 
Kmð1 þ
½I 
Ki þ
½I9 
Ki9 þ   Þþ½S 
ð2Þ
where [I] is the concentration of inhibitor and Ki is the inhibition
constant, which is deﬁned as:
Ki ¼
½E ½I 
½EI 
ð3Þ
If the inhibitors are irreversible, we assume the enzymes would
decay according to the following equation:
d½E 
dt
¼  K½E ½I ð 4Þ
where K is a constant.
When activators are involved in the catalysis, we use the following
equation:
d½S 
dt
¼
Kcatð1 þ
½A 
KI þ
½A9 
KI9Þ½Et ½S 
Km þ½ S 
ð5Þ
where [A] is the concentration of activator and KI is a constant.
PGE2 can upregulate 15-LOX through transcription in this
network. Based on the experimental data, we describe its effect with
the following equation:
d½E 
dt
¼
k½g 
2
½g 
2 þ K2 ð6Þ
where [g] is the concentration of PGE2 and K is a constant.
The ode15s routine of Matlab 6.5 (Mathworks, http://www.
mathworks.com) was used to solve the ODEs. LTB4 and x-LTB4
metabolic curves under different exogenous AA concentrations were
calculated. These calculated curves were ﬁt to the experimental data
by empirically modulating parameters that had no direct values from
published experiments, while the other parameters remained ﬁxed to
their experimental values. The parameter set that ﬁt the exper-
imental data well was chosen for further studies.
Simulating the therapeutic effects of the dual functional inhibitor and the
mixture. The inhibition behavior on different enzymes is assumed to
be independent and can be calculated by the following equations
(only competitive reversible inhibitors are studied here):
d½S 
dt
¼
Kcat½Et ½S 
Kmð1 þ
½I 
Ki þ
½I9 
Ki9 þ   Þþ½S 
½I ¼  Kon½E ½I þKoff½EI ð 7Þ
Ki ¼
½E ½I 
½EI 
¼
Koff
Kon
Figure 6. The Effect of the Mixture and the Dual-Functional COX-2/5-LOX
Inhibitors
(A) The effect of MR on the efficacy of the mixture of COX-2/5-LOX
inhibitors was simulated.
(B) The effect of DR on the efficacy of the dual functional COX-2/5-LOX
inhibitor was simulated.
(C) Comparison of the therapeutic effects of these two kinds of inhibitors.
The inhibition intensity on the production of LTs and PGs was calculated
to evaluate the efficacy of inhibitors, where I (Mix) is the inhibition
intensity of the mixture and I (Dual) is the inhibition intensity of the dual
functional inhibitor. ER is the relative activity of COX-2 to 5-LOX, which is
0.02 in the current model. CIt is the total concentration of inhibitors while
CEt is the total concentration of COX-2 and 5-LOX. DR is the relative
inhibition constant to different enzymes (DR¼Ki5-LOX / KiCOX-2), and MR is
the mixing ratio of the COX-2 inhibitor and the 5-LOX inhibitor (MR ¼
[COX-2] / [5-LOX]). The efficacy of these two types of inhibitors was
compared by the value of difference between I(Dual) and I(Mix).
doi:10.1371/journal.pcbi.0030055.g006
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The Arachidonic Acid Metabolic Networkwhere [I] is the concentration of inhibitor, and Ki is the dissociation
constant. We use these equations with the consideration that the
binding afﬁnity of drugs is usually strong and the necessary
concentration of inhibitors is in the same magnitude with the
concentration of the enzyme. Then the enzyme-inhibitor complex
cannot be neglected, and the above equations are required.
To evaluate the efﬁcacy of inhibitors, inhibition intensity on the
production of inﬂammatory mediators is deﬁned as:
II ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½PGs 1  ½ PGs 0
½PGs 0
 
½LTs 1  ½ LTs 0
½LTs 0
s
ð8Þ
where [PGs]1 is the concentration of PGs after taking drugs, [PGs]0 is
the concentration of PGs before treatment, [LTs]1 is the concen-
tration of LTs after taking drugs, and [LTs]0 is the concentration of
LTs before treatment.
We use the same value of total inhibition ability and total
concentration of the dual functional inhibitor and the mixture to
ensure the equality in the comparison. The total inhibition ability is
deﬁned as the product of inhibit constant to COX-2 and 5-LOX
(KiCOX-2 3 Ki5-LOX) and is ﬁxed to 1 3 10
 14 in all simulations. ER is
deﬁned as:
ER ¼
ACOX 2
A5 LOX
¼
CCOX 2  
Kcat;COX 2
Km;COX 2
C5 LOX  
Kcat;5 LOX
Km;5 LOX
ð9Þ
where A is the activity of enzyme, and C is the concentration. The ER
value in the current model is 0.02.
Experiments. Materials. LTB4, 20-OH-LTB4, 20-COOH-LTB4, 5-
HETE, 15-HETE, PGB2, MK886, CAY10404, and AA were purchased
from Cayman Chemical (http://www.caymanchem.com). The calcium
ionophore, A23187, was obtained from Acros Organics (http://www.
acros.com). Concentrations of the LTs and hydroxyeicosatetraenoic
acids were determined by UV spectroscopy at 270 nm and 236 nm,
respectively. PGB2 was used as an internal standard, and its
concentration was determined by UV spectroscopy at 278 nm
[e(PGB2) ¼ 26,000].
Preparation of PMNs from human blood. Following the reported
procedure [35], human PMNs were isolated from the venous blood of
healthy volunteers who had not ingested any aspirin-like compounds
in the preceding week. Blood was collected in the anticoagulant Na-
EDTA and was centrifuged at 100g for 10 min. The platelet-rich
plasma was discarded. The blood was then mixed with 6% dextran T-
500 in 0.01 M PBS (T500/PBS¼1:1). After 45 min, the upper layer that
contained the leukocytes was layered gently over lymphocyte
separation medium and centrifuged at 550g for 30 min to pellet the
cells. The residual erythrocytes were removed by osmotic hemolysis
with ice-cold water for 20 s. The mixture was washed twice by
centrifugation in 0.01 M PBS at 250g for 5 min and then resuspended
in PBS (.95% PMNs, ,5% monocytes and lymphocytes).
Effect of inhibitors on the network. PMNs were preincubated with
MK886 [36] (an inhibitor of 5-LOX), CAY10404 [37] (an inhibitor of
COX-2), and a combination of MK886 and CAY10404 at 37 8C for
10 min, respectively. To stimulate the PMNs, 10 lM A23187, 2 mM
Ca
2þ, and 2 mM Mg
2þ were added for 1 h at 37 8C. Incubations were
terminated by the addition of ethyl acetate (containing 160 ll acetic
acid/40 ml). PGB2 (100 ng) was added as an internal standard. The
upper solvent was evaporated under a stream of nitrogen, and the
residue was dissolved in 30 ll methanol.
Reverse-phase high-performance liquid chromatography (HPLC)
was used to assay 20-OH-LTB4, 20-COOH-LTB4, and 15-HETE [38].
HPLC was performed with an Agilent 1100 series instrument (http://
www.agilent.com). A column (Retasil C18, 4.6 3 200 mm cartridge, 5
lm particle size; Elite, http://las.perkinelmer.com) was used for
separation of the samples. Solvents A and B consisted of methanol–
water–acetic acid (10:90:0.05) and methanol–acetonitrile–acetic acid
(30:70:0.05), respectively. Lipids were eluted at a rate of 1.0 ml/min
with continuous monitoring for UV absorbance at 235 nm and 270
nm for detection of 15-HETE and LTs, respectively. The retention
times for 20-COOH-LTB4, 20-OH-LTB4, PGB2, and 15-HETE were
6.399, 6.603, 11.604, and 17.899 min, respectively.
Effect of AA on the network. Cells were preincubated with 0.1 mM,
0.5 mM, and 1 mM AA at 37 8C for 10 min. To stimulate PMNs, 10 lM
A23187, 2 mM Ca
2þ, and 2 mM Mg
2þwere then added for 1 h at 37 8C.
Incubations were terminated by the addition of ethyl acetate
(containing 160 ll acetic acid/40 ml). PGB2 (100 ng) was added as
an internal standard. The upper solvent was evaporated under a
stream of nitrogen, and the residue was dissolved in 30 ll methanol.
Again, reverse-phase HPLC was used to assay 20-OH-LTB4, 20-
COOH-LTB4, and 15-HETE as described above.
Supporting Information
Dataset S1. The SBML Model of the AA Metabolic Network in Human
PMNs
The serial number of metabolites, enzymes, and feedback regulations
used in the model is deﬁned in Protocol S1. Parameters are
summarized in Tables S1 and S2.
Found at doi:10.1371/journal.pcbi.0030055.sd001 (67 KB XML).
Protocol S1. Details of the AA Metabolic Network Model That Are
Not Mentioned in the Main Text
The AA metabolic network in human PMNs is constructed based on
KEGG and a survey of the literature. References used for model
construction and 24 ODEs used in simulations are listed.
Found at doi:10.1371/journal.pcbi.0030055.sd002 (214 KB DOC).
Table S1. Parameters of Feedback Regulations Used in the Model
Found at doi:10.1371/journal.pcbi.0030055.st001 (55 KB DOC).
Table S2. The Km and Kcat of Enzymes Used in the Model
Found at doi:10.1371/journal.pcbi.0030055.st002 (34 KB DOC).
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